53267-93-9

Basic information

• Product Name: Boc-O-methyl-L-tyrosine
• Synonyms: BOC-O-METHYL-L-TYROSINE;BOC-PHE(4-OME)-OH;BOC-P-METHOXY-PHE-OH;BOC-L-TYR(ME);BOC-L-TYR(ME)-OH;BOC-L-4-METHOXYPHE;BOC-4-METHOXYPHENYLALANINE;BOC-4-METHOXY-PHE-OH
• CAS NO: 53267-93-9
• Molecular Formula: C₁₅H₂₁NO₅
• Molecular Weight: 295.33
• Product Categories: Phenylalanine [Phe, F];Unusual Amino Acids;Boc-Amino Acids and Derivative;Boc-Amino acid series
• Mol File: 53267-93-9.mol
• Article Data: 22

Chemical Properties

• Boiling Point: 462 °C at 760 mmHg
• Flash Point: 233.2 °C
• Appearance: /Solid
• Density: 1.168 g/cm³
• Vapor Pressure: 2.47E-09mmHg at 25°C
• Refractive Index: 1.522
• Storage Temp.: Store at 0-5°C
• PKA: 3.00±0.10(Predicted)
• CAS DataBase Reference: Boc-O-methyl-L-tyrosine(CAS DataBase Reference)
• NIST Chemistry Reference: Boc-O-methyl-L-tyrosine(53267-93-9)
• EPA Substance Registry System: Boc-O-methyl-L-tyrosine(53267-93-9)

Safety Data

• WGK Germany: 3
• HazardClass: IRRITANT
• Hazardous Substances Data: 53267-93-9(Hazardous Substances Data)

Usage

Chemical Properties

White powder

Uses

Boc-Tyr(Me)-OH, is an amino acid building block used in peptide synthesis. With a growing peptide drug market the fast, reliable synthesis of peptides is of great importance.

InChI:InChI=1/C15H21NO5/c1-15(2,3)21-14(19)16-12(13(17)18)9-10-5-7-11(20-4)8-6-10/h5-8,12H,9H2,1-4H3,(H,16,19)(H,17,18)/t12-/m0/s1

Upstream product

• 1070-19-5 N-(tert-butyloxycarbonyl) azide 
• 6230-11-1 O-Methyltyrosine 
• 67423-44-3 (S)-2-amino-3-(4-methoxyphenyl)propanoic acid hydrochloride 
• 17355-19-0 methyl (S)-2-amino-3-(4-methoxyphenyl)propionate 
• 35448-10-3 oxalic acid mono-tert-butyl ester 
• 60-18-4 L-tyrosine 
• 3978-80-1 Boc-Tyr-OH 
• 24424-99-5 di-tert-butyl dicarbonate 
• 3417-91-2 L-tyrosine methyl ester HCl 
• 4326-36-7 (S)-N-(tert-butoxycarbonyl)tyrosine methyl ester 
• 74-88-4 methyl iodide 
• 77-78-1 dimethyl sulfate 
• 94790-24-6 (S)-methyl 2-((tert-butoxycarbonyl)amino)-3-(4-methoxyphenyl)propanoate 

Downstream Products

• 57183-05-8 tert-butyl [(S)-1-({(2S,3S,4R,5R)-5-[6-(dimethylamino)-9H-purin-9-yl]-4-hydroxy-2-(hydroxymethyl)tetrahydrofuran-3-yl}amino)-3-(4-methoxyphenyl)-1-oxopropan-2yl]carbamate 
• 231290-01-0 [2-[4-(2-fluoro-ethyl)-piperidin-1-yl]-1-(4-methoxy-benzyl)-2-oxo-ethyl]-carbamic acid tert-butyl ester 
• 126395-29-7 [(S)-2-hydroxy-1-(4-methoxybenzyl)ethyl]carbamic acid tert-butyl ester 
• 142995-38-8 Boc-Phe(4-OMe)-NMeBzl 
• 122900-19-0 N^α-tert-butyloxycarbonyl-O-methyl-(S)-tyrosine methylamide 
• 110205-97-5 [(S)-1-[(S)-1-[(1S,2R)-1-Cyclohexylmethyl-2-hydroxy-3-(propane-2-sulfonyl)-propylcarbamoyl]-2-(1H-imidazol-4-yl)-ethylcarbamoyl]-2-(4-methoxy-phenyl)-ethyl]-carbamic acid tert-butyl ester 
• 108868-76-4 [(S)-1-[(S)-1-[(1S,2S)-1-Cyclohexylmethyl-2-hydroxy-4-(4-methyl-pentanoylamino)-butylcarbamoyl]-2-(1H-imidazol-4-yl)-ethylcarbamoyl]-2-(4-methoxy-phenyl)-ethyl]-carbamic acid tert-butyl ester 
• 142410-15-9 1-(2,3-dideoxy-3-(N-t-butyloxycarbonyl-p-methoxy-L-phenylalanylamino)-α-L-erythro-pentofuranosyl)thymine 
• 142410-13-7 1-(2,3-dideoxy-3-(N-t-butyloxycarbonyl-p-methoxy-L-phenylalanylamino)-β-L-erythro-pentofuranosyl)thymine 
• 80361-99-5 6-(dimethylamino)-9-<3'-<amino>-5'-chloro-3',5'-dideoxy-β-D-ribofuranosyl>purine 
• 126686-66-6 Z-Thr--CAM 
• 94790-23-5 Boc-(OCH₃)-Tyr-D-Ala-Gly-Phe-Leu-OBzl 
• 142410-17-1 1-(2,3-dideoxy-3-(N-t-butyloxycarbonyl-p-methoxy-L-phenylalanylamino)-α-D-erythro-pentofuranosyl)thymine 
• 7479-01-8 O-methyl-L-tyrosine methyl ester hydrochloride 

Relevant articles and documents

INHIBITOR OF APOPTOSIS (IAP) PROTEIN ANTAGONISTS

Provided herein are compounds that modulate the activity of melanoma inhibitor of apoptosis (ML-IAP) protein, compositions comprising the compounds, and methods of using the compounds and compositions comprising the compounds.

EPHA4 CYCLIC PEPTIDE ANTAGONISTS AND METHODS OF USE THEREOF

Disclosed herein are compounds and methods of use thereof for the modulation of EphA4 receptor activity. In an aspect, is provided a method of treating or preventing a disease or disorder mediated by EphA4, comprising administering to a subject in need thereof a therapeutically effective amount of a compound as described herein, including certain embodiments, or the structural Formula (I), (l-A), (II), (III), (IV), (IV-1), (V), (Vl-A), (Vl-B), (VII-1), (VII-2), (VIII-1), or (VIII-2), or an enantiomer, a mixture of enantiomers, a mixture of two or more diastereomers, or an isotopic variant thereof; or a pharmaceutically acceptable salt, solvate, or hydrate thereof.

Preparation method of O-methyl-threonine/tyrosine

The invention relates to a preparation method of O-methyl-threonine/tyrosine. The preparation method mainly overcomes the disadvantages of the existing method that a toxic reagent is volatile, the reagent is dangerous, the steps are long, the yield is low, and the like. The preparation method of the O-methyl-threonine/tyrosine comprises the following steps: N-t-butyloxycarboryl-threonine/tyrosineis catalyzed by sodium hydroxide and reacts with dimethyl sulfate to generate N-t-butyloxycarboryl-O-methyl-threonine/tyrosine, and then t-butyloxycarboryl is removed from the N-t-butyloxycarboryl-O-methyl-threonine/tyrosine through acid substances to obtain the product O-methyl-threonine/tyrosine. The product has important application in the fields of antibiotics and polypeptide drugs.